Alvotech Warrant

Alvotech develops and manufactures biosimilar medicines for patients worldwide through its subsidiaries. Its portfolio targets autoimmune, eye, and bone disorders, as well as cancer. Key products include AVT02 (a biosimilar to Humira), AVT04 (a biosimilar to Stelara), AVT06 (a biosimilar to Eylea), AVT03 (a biosimilar to Xgeva and Prolia), AVT05 (a biosimilar to Simponi and Simponi Aria), AVT16 (a biosimilar to an Entyvio product), AVT23 (a biosimilar to Xolair), and AVT33 (a biosimilar to a Keytruda product in early phase development). Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.